4519 (4519) News
Follow 4519 (4519) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Chugai Pharmaceutical Nine-Month Profit Rises to JPY375.302 Billion
Chugai Pharmaceutical reported nine-month earnings of JPY375.302 billion, or JPY228.07 per share, compared with JPY305.602 billion and JPY185.70 per share a year earlier.
EARNINGS | Oct 27, 2026, 08:54 AM UTC
M
Chugai Pharmaceutical 9-Month Net Y375.30B vs. Y305.60B
Chugai Pharmaceutical reported net income of Y375.30B for nine months, versus Y305.60B.
EARNINGS | Oct 27, 2026, 08:00 AM UTC
L
Chugai Pharmaceutical's Pipeline Looking Increasingly Thin — Market Talk
Chugai Pharmaceutical's mid-to late-stage pipeline is looking increasingly thin, Jefferies analysts say in a note. Roche has discontinued development of GYM329 for obesity and returned the rights to Chugai. Investors hav
NEWS | Sep 29, 2026, 02:57 AM UTC
L
Roche Halts Development of Obesity Drug Candidate
By Adria CalatayudRoche Holding said it stopped work on one of its obesity-drug candidates, after clinical-trial data suggested the medicine wouldn't hit internal targets.The Swiss drugmaker said it returned rights to th
NEWS | Sep 28, 2026, 12:34 PM UTC
L
Chugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Chugai Pharmaceutical Co Ltd TSE:4519
NEWS | Sep 28, 2026, 07:04 AM UTC